PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Regulation FD Disclosure

PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Regulation FD Disclosure
Item 7.01.

Story continues below

Pulmatrix, Inc. Exhibit
EX-99.1 2 d582909dex991.htm EX-99.1 EX-99.1 PULMATRIX Corporate Overview August 2018 NASDAQ: PULM Exhibit 99.1 Safe Harbor This presentation contains forward-looking statements. All statements other than statements of historical fact contained herein,…
To view the full exhibit click here


Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

An ad to help with our costs